

Starpharma and Monash awarded STEM+ Business Fellowships

Melbourne, Australia; 9 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded \$300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding, across two separate programs, will allow Starpharma and MIPS to further advance collaborative programs utilising Starpharma's Targeted DEP[®] platform.

Starpharma's Targeted DEP[®] platform uses DEP[®] conjugates, which incorporate antibodies, to enhance drug concentration at the disease site and reduce off-target toxicity to improve therapeutic outcomes for cancer patients. The application of this funding will build upon Starpharma's impressive Targeted DEP[®] Herceptin[®] conjugate results reported in an ovarian cancer model¹. Starpharma has also partnered with two world-leading antibody-drug conjugate (ADC) companies on additional Targeted DEP[®] programs.

Starpharma CEO, Dr Jackie Fairley, commented "We are delighted to collaborate once again with the internationally renowned researchers in drug delivery from Monash Institute of Pharmaceutical Sciences. This collaboration will expand the activities around our novel Targeted DEP[®] conjugates and is expected to generate exciting technical results and considerable commercial benefits by way of new intellectual property and commercialisation opportunities for Starpharma" said Dr Fairley.

"The SIEF STEM+ business fellowship program is a great opportunity to further our long standing and highly successful collaboration with Starpharma and to further develop next generation targeting approaches for the DEP[®] dendrimer drug delivery platform" said MIPS Director, Professor Chris Porter.

¹ See ASX announcements on 2 February 2016 and 16 November 2015.

About the SIEF STEM+ Business Fellowship program

The Science and Industry Endowment Fund (SIEF) provides grants to science and scientists for the purposes of assisting Australian industry, furthering the interests of the Australian community and contributing to the achievement of Australian national objectives. SIEF's STEM+ Business Fellowship program is supporting collaboration between Small and Medium Enterprises (SMEs) and the research sector to implement ideas with commercial potential and is creating a cohort of industry-savvy Early Career Researchers capable of addressing national challenges.

About Monash Institute of Pharmaceutical Sciences (MIPS)

MIPS is Australia's largest, most experienced and successful group of pharmaceutical scientists. MIPS integrates research from four key discipline-based themes including: Medicinal Chemistry and Drug Action; Centre for Drug Candidate Optimisation; Drug Delivery, Disposition and Dynamics; and Drug Discovery Biology - to identify, develop, optimise and deliver new drug treatments, ultimately translating basic research into clinical trials. MIPS has long-term collaborative research programs with more than 20 biotechnology and pharmaceutical companies, including strong partnerships with industry leaders such as Servier and GlaxoSmithKline.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing a number of products internally and others via commercial partnerships.

VivaGel®: Starpharma's portfolio includes late stage women's health products based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer. VivaGel® formulated as a water based gel and delivered vaginally - VivaGel® BV - has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and has recently completed clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand. Starpharma has also signed separate license agreements with Ansell Limited (ASX:ANN), Okamoto Industries. Inc., (TSE: JP3192800005), Sky and Land (China) and Koushan Pharmed (Iran) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia and in Canada under Ansell's Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, Manix®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

DEP®: The other major part of Starpharma's pharmaceuticals business is its proprietary DEP® drug delivery platform. Starpharma has both partnered and internal DEP® programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development by the Company. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). In the partnered area, AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of a number of AstraZeneca oncology compounds.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [Linkedln](https://www.linkedin.com/company/starpharma)

Media

WE Buchan Consulting

Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.